Skip to main content
editor@theusajournals.com | Oscar Publishing Services Journal Home

American Journal Of Biomedical Science & Pharmaceutical Innovation

Peer Reviewed | Open Access | E-ISSN: 2771-2753
Published Article

Thrombin-Activatable Fibrinolysis Inhibitor in Stable Angina Pectoris

Thrombin-Activatable Fibrinolysis Inhibitor in Stable Angina Pectoris

  • Zakirovа М.B.
    Republican Specialized Scientific-Practical Center of Hematology, Uzbekistan
  • Iskandarova Sh.Т.
    Таshkent State Medical University, Uzbekistan
Chronic coronary syndrome stable angina endogenous fibrinolysis

Impairment of endogenous fibrinolysis is considered a component of residual atherothrombotic risk. Data regarding the thrombin-activable fibrinolysis inhibitor (TAFI) in the context of chronic coronary syndromes remain inconsistent. This study aimed to evaluate the levels of TAFI and related hemostatic factors in patients with stable angina, determine their variation across functional classes, and describe the one-year clinical course of a specific subgroup characterized by high TAFI levels.

Elevated levels of TAFI and associated hemostatic factors are linked to a higher functional class of stable angina. These findings support the need for prospective validation of TAFI, utilizing individual patient data, standardized clinical endpoints, and multivariable adjustment.

Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415–3537. doi: 10.1093/eurheartj/ehae177

Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023;148:e9–e119. doi: 10.1161/CIR.0000000000001168

Sillen M, Declerck PJ. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review. Int J Mol Sci. 2021;22(7):3670. doi: 10.3390/ijms22073670

Ząbczyk M, Ariëns RAS, Undas A. Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice. Cardiovasc Res. 2023;119(1):94–111. doi: 10.1093/cvr/cvad017

Schroeder V, Chatterjee T, Mehta H, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost. 2002;88(6):1020–1025. doi: 10.1055/s-0037-1613349

Fernandes AB, Lima LM, Sousa MO, et al. Impaired fibrinolysis in angiographically documented coronary artery disease. Adv Hematol. 2015;2015:214680. doi: 10.1155/2015/214680

Tregouet DA, Schnabel R, Alessi MC, et al. Activated TAFI levels are associated with cardiovascular death in coronary artery disease: the AtheroGene study. J Thromb Haemost. 2009;7(1):49–57. doi: 10.1111/j.1538-7836.2008.03221.x

Zhao M, Zhao D, Li Y, et al. A Case-Control Study of the Dose-Response Relationship Between TAFI and Acute Myocardial Infarction. Front Cardiovasc Med. 2022;9:823381. doi: 10.3389/fcvm.2022.823381

Farag M, Spinthakis N, Gue YX, et al. Impaired endogenous fibrinolysis in STEMI patients undergoing primary PCI predicts recurrent cardiovascular events: the RISK PPCI study. Eur Heart J. 2019;40(3):295–305. doi: 10.1093/eurheartj/ehy656

Sumaya W, Wallentin L, James SK, et al. Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Heart J. 2018;39(13):1078–1085. doi: 10.1093/eurheartj/ehy013

Kraler S, Liberale L, Tirandi A, et al. The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk. Eur Heart J. 2026;47(28):3693–3707. doi: 10.1093/eurheartj/ehaf979

von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Lancet. 2007;370(9596):1453–1457. doi: 10.1016/S0140-6736(07)61602-X

Welch BL. On the comparison of several mean values: an alternative approach. Biometrika. 1951;38(3–4):330–336. doi: 10.1093/biomet/38.3-4.330

Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6(2):65–70.

Muborakkhon Zokirova, Kayumov Abdurakhman, Nargiza Nurillaeva and Jakhongir Khaydarov An Integrated Model of Cardiotoxicity: Interaction of Age, Sex, and Genetic Polymorphisms in Patients with Acute Leukemia. Biomedicines 2026, 14(9), 1929; https://doi.org/10.3390/biomedicines14091929 (registering DOI) - 28 Aug 2026